Trial · NCT03605849
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 200 mg | Participants With TEAEs | 98 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 400 mg | Participants With TEAEs | 89 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Placebo | Participants With TEAEs | 123 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | De Novo Centanafadine SR 400 mg | Participants With TEAEs | 91 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 200 mg | Participants With Mild TEAE | 73 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 400 mg | Participants With Mild TEAE | 59 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Placebo | Participants With Mild TEAE | 92 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | De Novo Centanafadine SR 400 mg | Participants With Mild TEAE | 70 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 200 mg | Participants With Moderate TEAE | 58 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 400 mg | Participants With Moderate TEAE | 53 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Placebo | Participants With Moderate TEAE | 75 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | De Novo Centanafadine SR 400 mg | Participants With Moderate TEAE | 50 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 200 mg | Participants With Severe TEAE | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Centanafadine SR 400 mg | Participants With Severe TEAE | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | Prior Placebo | Participants With Severe TEAE | 7 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity | De Novo Centanafadine SR 400 mg | Participants With Severe TEAE | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03605849/results